CTAG1B and colorectal cancer: The authors could detect serum NY-ESO-1 autoantibodies across all cancers, with the highest frequency in esophageal cancer (32%), followed by lung cancer (13%), hepatocellular cancer (11%), prostate and gastric cancer (10%), colorectal cancer (8%), and breast cancer (7%).